Read by QxMD icon Read

European Journal of Gastroenterology & Hepatology

Stéphane Nahon, Toulsie Ramtohul, Thierry Paupard, Mehdi Belhassan, Emeline Clair, Vered Abitbol
INTRODUCTION: Delayed diagnosis of inflammatory bowel disease (IBD) has become a major issue, particularly in terms of the presence of nonspecific and heterogeneous clinical signs. This study aimed to identify changes over time in the epidemiological characteristics and clinical presentation of IBD in a French cohort. PATIENTS AND METHODS: Sociodemographic data from patients at three French hospitals (age, sex, country of origin, smoking habits) and characteristics of IBD [diagnostic delay, phenotype, location, first symptoms, first test suggesting diagnosis (endoscopy, imaging examination)] were collected in a computerized database (Focus_MICI)...
July 12, 2018: European Journal of Gastroenterology & Hepatology
Christina Sølund, Ellen S Andersen, Belinda Mössner, Alex L Laursen, Birgit T Røge, Mette S Kjær, Jan Gerstoft, Peer B Christensen, Martin S Pedersen, Kristian Schønning, Ulrik Fahnøe, Jens Bukh, Nina Weis
OBJECTIVE: New potent direct-acting antiviral (DAA) regimens against hepatitis C virus have been approved in recent years. However, information about the rate of adverse events (AEs) across different DAA regimens is limited. We aimed to evaluate differences in AEs and treatment efficacy in patients with chronic hepatitis C (CHC), genotype (GT) 1 or 3, randomized to two different treatment arms, correspondingly. PATIENTS AND METHODS: We randomly assigned 96 patients in a 1 : 1 ratio, to treatment for 12 weeks with either paritaprevir/ombitasvir/ritonavir/dasabuvir/ribavirin (RBV) or ledipasvir/sofosbuvir (SOF)/RBV if infected with GT1 (72 patients) or to daclatasvir/SOF/RBV for 12 weeks or SOF/RBV for 24 weeks, if infected with GT3 (24 patients)...
July 9, 2018: European Journal of Gastroenterology & Hepatology
Chung-Yu Chang, Wei-Yao Hsieh, Gar-Yang Chau, Ping-Hsien Chen, Chien-Wei Su, Ming-Chih Hou, Hao-Jan Lei, Teh-Ia Huo, Yi-Hsiang Huang, Han-Chieh Lin, Jaw-Ching Wu
OBJECTIVE: The predictive value of esophageal varices (EV) in determining the patient outcome in hepatocellular carcinoma (HCC) remains unresolved. We aimed to assess the impact of EV on the prognosis of HCC patients after surgical resection. MATERIALS AND METHODS: We consecutively enrolled 446 treatment-naive HCC patients who underwent surgical resection and esophagogastroduodenoscopy from 2003 to 2015. Prognostic factors were analyzed using the Cox proportional hazards model and a propensity score matching analysis...
July 9, 2018: European Journal of Gastroenterology & Hepatology
Gonçalo Nunes, Mariana Brito, Carla Adriana Santos, Jorge Fonseca
Clinical nutrition is emerging as a major area in gastroenterology practice. Most gastrointestinal disorders interfere with digestive physiology and compromise nutritional status. Refeeding syndrome (RS) may increase morbidity and mortality in gastroenterology patients. Literature search using the keywords "Refeeding Syndrome", "Hypophosphatemia", "Hypomagnesemia" and "Hypokalemia". Data regarding definition, pathophysiology, clinical manifestations, risk factors, management and prevention of RS were collected...
July 9, 2018: European Journal of Gastroenterology & Hepatology
Veeravich Jaruvongvanich, Kittika Poonsombudlert, Patompong Ungprasert
Acid secretion inhibitors are usually prescribed to promote the healing of artificial ulcers caused by endoscopic submucosal dissection (ESD) to reduce the risk of gastric perforation and delayed bleeding. Vonoprazan is a newer agent that has been shown to be more potent than a proton-pump inhibitor (PPI). However, it remains unclear whether vonoprazan is more effective than PPI in promoting healing of ulcers caused by ESD. Medline and Embase databases were searched through January 2018 for studies that compared the rate of complete healing of ulcers caused by ESD and post-ESD delayed bleeding in patients who received vonoprazan versus those who received PPI after ESD...
July 6, 2018: European Journal of Gastroenterology & Hepatology
Tawfik Khoury, Divya Nadella, Alex Wiles, Caitlin Marshall, Manoj Kumar, Gilad Shapira, Nicholas Ludvik, Alan Schumann, Mahmud Mahamid, Meir Mizrahi
BACKGROUND: Gastric varices (GV) manifest in almost one-fifth of the patients with portal hypertension. Although primary pharmacological prevention of esophageal varices has been identified, there are limited therapeutic options that are optimal for GV bleeding. Recently, the use of endoscopic ultrasound (EUS)-guided angiotherapy [cyanoacrylate (CA) and coils] was introduced for the treatment of GV. Although CA injection is the recommended first-line therapeutic modality, it is associated with systemic, life-threatening embolization as well as technical instrumental challenges...
July 5, 2018: European Journal of Gastroenterology & Hepatology
Katharina Guilcher, Nicolas Fournier, Alain Schoepfer, Susanne Schibli, Johannes Spalinger, Christian Braegger, Andreas Nydegger
BACKGROUND AND AIM: During the past decade, several new drugs were approved for the treatment of pediatric inflammatory bowel disease (IBD). We aimed to evaluate if and how pharmacologic treatment options for pediatric IBD in Switzerland have changed over time. PATIENTS AND METHODS: Data from the pediatric Swiss IBD Cohort Study, a national prospective cohort study initiated in 2006, were analyzed. Patients were divided into two groups: patients with IBD diagnosis until 2009 (168 patients) and patients with IBD diagnosis in 2010 and after (210 patients)...
July 5, 2018: European Journal of Gastroenterology & Hepatology
Bobby Lo, Mette Julsgaard, Marianne Kajbæk Vester-Andersen, Ida Vind, Johan Burisch
BACKGROUND: The inflammatory bowel disease disability index (IBD-DI) was developed recently. The aim was to translate the IBD-DI into Danish and validate it for future clinical studies and practice, and to assess the level of disability among IBD patients. PATIENTS AND METHODS: The IBD-DI was translated using a transcultural adaptation method. Between January and December 2017, patients from three outpatient clinics in three different regions in Denmark were given the final version of the IBD-DI for self-completion...
July 3, 2018: European Journal of Gastroenterology & Hepatology
Lucas A Hill, Ronnie J Delmonte, Barbara Andrews, Lisa Richards, Robin Soto, Summer Collier, Alexander Kuo, Edward Cachay
BACKGROUND: The availability of direct-acting antivirals (DAA) for the treatment of hepatitis C (HCV) has resulted in the ability to safely and effectively treat patients with cirrhosis and end-stage liver disease. However, information is limited with regard to the impact of DAA treatment on inpatient health-related resource utilization in patients with advanced HCV-related cirrhosis. We aimed to ascertain the impact of DAA treatment on the frequency of liver-related hospitalizations and associated costs in patients with cirrhosis...
July 2, 2018: European Journal of Gastroenterology & Hepatology
Sandra Bohn Thomsen, Marianne Kiszka-Kanowitz, Klaus Theede, Lise Lotte Gluud, Anette Mertz Nielsen
OBJECTIVE: Two meta-analyses have found that the risk of relapse in Crohn's disease (CD) was ~40 and 50% 1 and 2 years, respectively, after withdrawal of anti-tumour necrosis factor-α (anti-TNFα). The aim of this study was to evaluate relapse rates in CD when thiopurine therapy was optimized before anti-TNFα withdrawal. PATIENTS AND METHODS: An observational study was conducted including patients with CD in remission with optimized thiopurine therapy before anti-TNFα withdrawal...
July 2, 2018: European Journal of Gastroenterology & Hepatology
Olalekan Akanbi, Adeyinka C Adejumo, Nasir Saleem, Frantz Francisque, Mohanad Soliman, Gbolahan O Ogunbayo
BACKGROUND: Sickle cell disease (SCD) is the most common inheritable hematologic disorder in the USA and is associated with ischemic organ diseases. SCD-associated ischemic bowel disease is increasing being recognized, and studies on the hospitalization outcomes of such patients are limited. OBJECTIVE: This study aimed to compare the inpatient outcomes of ischemic bowel disease among patients with SCD compared with patients without SCD. MATERIALS AND METHODS: This is a case-control study using data from the National Inpatient Sample Database (2007-2014)...
June 27, 2018: European Journal of Gastroenterology & Hepatology
Tirzah M Lopes-Secundoa, Tiago Sevá-Pereira, Bárbara R Correa, Natalie C M Silva, Marcello R Imbrizi, Marlone Cunha-Silva, Elza C Soares, Jazon R S Almeida
INTRODUCTION: Bacterial infection is present in up to 30% of hospitalized cirrhotic patients. It can lead, even after its resolution, to organ dysfunction and even acute-on-chronic liver failure (ACLF). It is the precipitating factor of ACLF in one third of the cases and is the main cause of mortality in patients with liver cirrhosis. OBJECTIVES: The aim of this study was to evaluate the prevalence and identify early risk factors for severe ACLF and death in hospitalized patients with liver cirrhosis with bacterial infection...
June 25, 2018: European Journal of Gastroenterology & Hepatology
Laura Gómez-Escolar Viejo, Antonio García Herola, Isabel Sáez Lloret, Fernando Sánchez Ruano, Inmaculada Clemente Paulino, Cristina Quílez Ivorra, Isabel Almenta Saavedra, David Martínez Pérez, Jaime Valverde de la Osa
PURPOSE: The aim was to estimate seroprevalence and prevalence of hepatitis C virus (HCV) infection in a small health area of the Valencian Community, Spain. PATIENTS AND METHODS: This is a descriptive cross-sectional study aimed at estimation of HCV infection prevalence in the whole adult population (25-70 years old), that is, a pilot study for an eventual population-based screening program. RESULTS: A total of 5849 participants aged 25-70 years (51% male) were invited to participate by regular mail...
June 22, 2018: European Journal of Gastroenterology & Hepatology
Antonio Aguilera, Javier Rodríguez-Calviño, Carmen de Mendoza, Vincent Soriano
BACKGROUND: The hepatitis delta virus (HDV) causes the most aggressive form of chronic viral hepatitis. As HDV replication requires hepatitis B virus (HBV), HDV screening is limited to HBsAg+ carriers. To date, individuals with HDV-antibodies and markers of resolved hepatitis B are considered cured. However, a subset shows elevated liver enzymes and hepatic fibrosis. Could they represent HBsAg-seronegative occult HDV infections? METHODS: We tested for HDV-antibodies 406 individuals with markers of past HBV exposure...
June 20, 2018: European Journal of Gastroenterology & Hepatology
Dimitrios Oikonomou, Georgios Georgiopoulos, Vassiliki Katsi, Chris Kourek, Constantinos Tsioufis, Alexendra Alexopoulou, Evaggelia Koutli, Dimitrios Tousoulis
OBJECTIVE: To provide a comprehensive review summarizing the existing evidence on the association between nonalcoholic fatty liver disease (NAFLD) and hypertension (HT) independent of other components of metabolic syndrome. METHODS: We searched the literature through Medline and the Cochrane Library for studies evaluating the relationship between hypertension and fatty liver disease. RESULTS: Studies testing this association are limited, but agree that HT and fatty liver disease are inter-related independent of other components of the metabolic syndrome such as obesity and diabetes mellitus...
June 18, 2018: European Journal of Gastroenterology & Hepatology
Dan-Qin Sun, Chen-Fei Zheng, Feng-Bin Lu, Sven Van Poucke, Xiao-Ming Chen, Yong-Ping Chen, Lai Zhang, Ming-Hua Zheng
BACKGROUND AND AIM: Serum lactate levels are routinely measured in critically ill patients with cirrhosis, and hyperlactatemia is a common finding, but its prognostic value remains controversial. Our aim was to examine whether serum lactate level could be used as a predictor of outcome in critically ill patients with cirrhosis (CICP) with acute kidney injury (AKI). PATIENTS AND METHODS: In this study, we included 480 consecutive patients with cirrhosis admitted to ICU, complicated with AKI, and were followed up for 365 days...
June 18, 2018: European Journal of Gastroenterology & Hepatology
Olubunmi O Olubamwo, Jyrki K Virtanen, Ari Voutilainen, Jussi Kauhanen, Jussi Pihlajamäki, Tomi-Pekka Tuomainen
BACKGROUND: Fatty liver disease (FLD) has been identified as constituting cardiometabolic risk. However, evidence on the association of fatty liver index (FLI) with cardiovascular disease (CVD) is largely cross-sectional, with limited evidence on the predictability of incident CVD, and specifically, acute myocardial infarction (AMI). Therefore, we aimed to investigate the prospective associations between fatty liver as estimated by FLI and incident CVD, and specifically AMI, in the Kuopio Ischaemic Heart Disease Risk Factor Study cohort...
June 16, 2018: European Journal of Gastroenterology & Hepatology
Mona Rezapour, Artin Galoosian, Benny Liu, Taft Bhuket, Robert J Wong
OBJECTIVE: Inflammatory bowel disease (IBD) patients with Clostridium difficile co-infection (CDCI) have an increased risk of morbidity and mortality. We aim to evaluate the impact of CDCI on in-hospital outcomes among adults with IBD hospitalized in the USA. PATIENTS AND METHODS: Using the 2007-2013 Nationwide Inpatient Sample, hospitalizations among US adults with Crohn's disease (CD), ulcerative colitis (UC) and CDCI were identified using ICD-9 coding. Hospital charges, hospital length of stay (LOS), and in-hospital mortality was stratified by CD and UC and compared using χ-testing and Student's t-test...
June 11, 2018: European Journal of Gastroenterology & Hepatology
Rengasamy P Shanmugam, Selvakumar Balakrishnan, Hemalatha Varadhan, Vivekanandan Shanmugam
OBJECTIVES: This study aims to estimate the prevalence of hepatitis B (HBV) and C (HCV) in the population through field-screening camps conducted by Chennai Liver Foundation, in the southern state of Tamil Nadu, India. This is the largest population-based study from Tamil Nadu. PATIENTS AND METHODS: A total of 75 camps were conducted across 14 districts of Tamil Nadu (2014-2017). Screening was done by rapid point-of-care assays (SD-bioline tests) and confirmed by enzyme-linked immunosorbent assay (Monolisa tests)...
June 8, 2018: European Journal of Gastroenterology & Hepatology
Jialiang Chen, Dongying Xue, Fangyuan Gao, Le Tao, Yuxin Li, Qun Zhang, Rui Wang, Le Sun, Xue Yang, Yao Liu, Bingbing Zhu, Shuaishuai Niu, Xianbo Wang
AIMS: The biochemical response after ursodeoxycholic acid (UDCA) treatment contributes toward predicting the prognosis for primary biliary cholangitis (PBC) patients. This study aimed to establish a score model that can be used for predicting the biochemical response. PATIENTS AND METHODS: A total of 218 patients in the derivation group and 66 patients in the verification group were enrolled. Response endpoints were based on the Barcelona criteria combined with the Paris I criteria...
June 8, 2018: European Journal of Gastroenterology & Hepatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"